NCCN VERSION 2 2015

NCCN Guidelines Version 2.2015 Inflammatory Breast Cancer

NCCN Guidelines Index Breast Cancer Table of Contents Discussion

TREATMENT k

• Complete planned chemotherapy regimen course if not completed preoperatively plus endocrine treatment if ER-positive and/or PR-positive (sequential chemotherapy followed by endocrine therapy). • Complete up to one year of HER2-targeted therapy if HER2-positive (category 1). May be administered concurrently with radiation therapy n and with endocrine therapy if indicated.

Total mastectomy + level l/ll axillary dissection + radiation therapy to chest wall and supraclavicular nodes (plus internal mammary nodes if involved, consider internal mammary nodes if not clinically involved [category 3]) ± delayed breast reconstruction l

Response

Response

See above pathway

Consider additional systemic chemotherapy m and/or preoperative radiation

No response

No response

Individualized treatment

Note: All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged. k Patients with stage IV or recurrent IBC should be treated according to the guideline for recurrence/stage IV disease ( BINV-17 to BINV-22). l See Principles of Breast Reconstruction Following Surgery (BINV-H) . m See Chemotherapy Regimens for Recurrent or Metastatic Breast Cancer (BINV-N) . n See Principles of Radiation Therapy (BINV-I) .

IBC-2

Version2.2015, 03/11/2015© National Comprehensive Cancer Network, Inc. 2015,All rights reserved.The NCCN Guidelines ® and this illustration may not be reproduced in any form without the express written permission of NCCN ® .